Master Interactive Reference
35 Diagnostic Reference Pages5 Clinical Sections + Calculators
Steatotic Liver Portal • Clinical & Patient Diagnostic Guide

Biomarkers and Diagnostic Tests in MASH

Complete clinical and plain-language guide to noninvasive blood scores, interactive calculators, proprietary biomarkers, elastography, MRI fat quantification, and global practice guidelines.

What This Means for Patients

For years, the only way to know how much scarring (fibrosis) or active inflammation you had in your liver was an invasive needle biopsy. Today, we have a practical toolkit of blood calculations, specialized fibrosis blood panels, ultrasound stiffness scans, and MRI techniques that let you and your doctor measure liver fat, stage scarring safely, and even qualify for FDA-approved MASH treatments without a routine biopsy.

Use the interactive directory below or the Diagnostics dropdown menu above to look up any test on your lab report, try our private in-browser calculators (FIB-4, SAFE, and Standard Drink / MetALD), and see how 14 medical societies across liver, diabetes, heart, endocrine, and pediatric care align on protecting your liver.

While histology remains the reference standard for microscopic cellular grading, noninvasive blood and imaging tools now assess fibrosis risk, predict clinical outcomes, and qualify eligible F2–F3 MASH patients for FDA-approved therapies without routine biopsy.1,2

MASLD/MetALD/MASH spectrum, AASLD 2023 & 2025 NILDA, ADA 2026, EASL-EASD-EASO 2024, specialty guidelines, and biopsy-free drug eligibility.

Side-by-side summary tables of clinical cutoffs, strengths, limitations, and intended uses across blood scores and imaging modalities.

Combined imaging-plus-blood composite scores (MEFIB, MAST, FAST, Agile 3+, Agile 4), longitudinal outcome monitoring, liver biopsy pathology, and score confounders.